The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan

Journal of Controlled Release

Volumn 174, Issue 1, 2014, Pages 88-97

  Fugit, Kyle D ^a   Anderson, Bradley D ^a  

^a University of Kentucky   (United States)

Author keywords

Kinetics; Liposomes; Membrane binding; Nanotechnology; Permeability; Topotecan

Indexed keywords

ACID DISSOCIATION CONSTANTS; CONTROLLABLE RELEASE; HYDROLYSIS KINETICS; LIPOSOMAL DELIVERY SYSTEM; LIPOSOMAL DRUG DELIVERY SYSTEMS; LIPOSOMAL FORMULATION; MEMBRANE BINDING; TOPOTECAN;

CARBOXYLATION; DISSOCIATION; DRUG DELIVERY; ENCAPSULATION; ENZYME KINETICS; ESTERS; HYDROLYSIS; KINETICS; LIPOSOMES; MATHEMATICAL MODELS; MECHANICAL PERMEABILITY; NANOTECHNOLOGY; OPTIMIZATION; TUMORS;

LOADING;

CAMPTOTHECIN; LACTONE; TOPOTECAN;

ARTICLE; CALIBRATION; DRUG RELEASE; DRUG STRUCTURE; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS KINETICS; KINETICS; LIPOSOMAL DELIVERY; MATHEMATICAL MODEL; MEMBRANE BINDING; MEMBRANE PERMEABILITY; NANOTECHNOLOGY; PH; PRIORITY JOURNAL; SUSPENSION;

KINETICS; LIPOSOMES; MEMBRANE BINDING; NANOTECHNOLOGY; PERMEABILITY; TOPOTECAN;

HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; LIPOSOMES; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84888784554     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.11.003     Document Type: Article

References (61)

1. D.C. Drummond, C.O. Noble, M.E. Hayes, J.W. Park, and D.B. Kirpotin Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development J. Pharm. Sci. 97 2008 4696 4740
2. G.J.R. Charrois, and T.M. Allen Rate of biodistribution of STEALTH® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity Biochim. Biophys. Acta 1609 2003 102 108 (Pubitemid 36044071)
3. F. Yuan, M. Leunig, S.K. Huang, D.A. Berk, D. Papahadjopoulos, and R.K. Jain Mirovascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res. 54 1994 3352 3356 (Pubitemid 24225946)
4. A. Chonn, S.C. Semple, and P.R. Cullis Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes J. Biol. Chem. 267 1992 18759 18765
5. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 41 2001 189 207
6. A.A. Gabizon Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects J. Drug Target. 10 2002 535 538 (Pubitemid 36124351)
7. S. O'Brien, G. Schiller, J. Lister, L. Damon, S. Goldberg, W. Aulitzky, D. Ben-Yehuda, W. Stock, S. Coutre, D. Douer, L.T. Heffner, M. Larson, K. Seiter, S. Smith, S. Assouline, P. Kuriakose, L. Maness, A. Nagler, J. Rowe, M. Schaich, O. Shpilberg, K. Yee, G. Schmieder, J.A. Silverman, D. Thomas, S.R. Deitcher, and H. Kantarjian High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia J. Clin. Oncol. 31 2013 676 683
8. G. Batist, K.A. Gelmon, K.N. Chi, W.H. Miller, S.K.L. Chia, L.D. Mayer, C.E. Swenson, A.S. Janoff, and A.C. Louie Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors Clin. Cancer Res. 15 2009 692 700
9. M. Montanari, F. Fabbri, E. Rondini, G.L. Frassineti, R. Mattioli, S. Carloni, E. Scarpi, W. Zoli, D. Amadori, and G. Cruciani Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer Tumori 98 2012 696 701
10. S. Koudelka, and J. Turanek Liposomal paclitaxel formulations J. Control. Release 163 2012 322 334
11. J.F. Deeken, R. Slack, G.J. Weiss, R.K. Ramanathan, M.J. Pishvaian, J. Hwang, K. Lewandowski, D. Subramaniam, A.R. He, I. Cotarla, A. Rahman, and J.L. Marshall A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies Cancer Chemother. Pharmacol. 71 2013 627 633
12. G.J. Kaspers, M. Zimmermann, D. Reinhardt, B.E. Gibson, R.Y. Tamminga, O. Aleinikova, H. Armendariz, M. Dworzak, S.Y. Ha, H. Hasle, L. Hovi, A. Maschan, Y. Bertrand, G.G. Leverger, B.I. Razzouk, C. Rizzari, P. Smisek, O. Smith, B. Stark, and U. Creutzig Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group J. Clin. Oncol. 31 2013 599 607
13. C. Mamot, R. Ritschard, A. Wicki, G. Stehle, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, and C. Rochlitz Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study Lancet Oncol. 13 2012 1234 1241
14. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, U.B. Nielsen, J.D. Marks, C.C. Benz, and J.W. Park Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy Cancer Res. 66 2006 6732
15. C.O. Noble, M.T. Krauze, D.C. Drummond, Y. Yamashita, R. Saito, M.S. Berger, D.B. Kirpotin, K.S. Bankiewicz, and J.W. Park Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy Cancer Res. 66 2006 2801 2806
16. N. Patankar, D. Waterhouse, D. Strutt, M. Anantha, and M. Bally Topophore C: A liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer Invest. New Drugs 31 2013 46 58
17. E.C. Ramsay, M. Anantha, J. Zastre, M. Meijs, J. Zonderhuis, D. Strutt, M.S. Webb, D. Waterhouse, and M.B. Bally Irinophore C: A liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors Clin. Cancer Res. 14 2008 1208 1217 (Pubitemid 351302570)
18. A. Romiti, M.C. Cox, I. Sarcina, R. Rocco, C. D'Antonio, V. Barucca, and P. Marchetti Metronomic chemotherapy for cancer treatment: a decade of clinical studies Cancer Chemother. Pharmacol. 2013 1 21
19. D.F.S. Kehrer, O. Soepenberg, W.J. Loos, J. Verweij, and A. Sparreboom Modulation of camptothecin analogs in the treatment of cancer: a review Anti-Cancer Drugs 12 2001 89 105 (Pubitemid 32207358)
20. V.M. Santana, W.C. Zamboni, M.N. Kirstein, M. Tan, T. Liu, A. Gajjar, P.J. Houghton, and C.F. Stewart A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors Clin. Cancer Res. 9 2003 633 640 (Pubitemid 36182595)
21. S. Modi, T.-X. Xiang, and B.D. Anderson Enhanced active liposomal loading of a poorly soluble ionizable drug using supersaturated drug solutions J. Control. Release 162 2012 330 339
22. S. Clerc, and Y. Barenholz A quantitative model for using acridine orange as a transmembrane pH gradient probe Anal. Biochem. 259 1998 104 111 (Pubitemid 28247057)
23. D. Zucker, D. Marcus, Y. Barenholz, and A. Goldblum Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties J. Control. Release 139 2009 73 80
24. B. Ceh, and D.D. Lasic A rigorous theory of remote loading of drugs into liposomes Langmuir 11 1995 3356 3368
25. B. Čeh, and D.D. Lasic A rigorous theory of remote loading of drugs into liposomes: transmembrane potential and induced pH-gradient loading and leakage of liposomes J. Colloid Interface Sci. 185 1997 9 18 (Pubitemid 27462709)
26. T.-X.X. Vijay Joguparthi, and Bradley D. Anderson Liposome transport of hydrophobic drugs: gel phase lipid bilayer permeability and partitioning of the lactone form of a hydrophobic camptothecin, DB-67 J. Pharm. Sci. 97 2008 400 420
27. B.D.A. Vijay Joguparthi Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH J. Pharm. Sci. 97 2008 433 454
28. J.N.M.D. Bruce, R.L.M.D. Fine, P.M.D.P. Canoll, J.M.D. Yun, B.C.M.D. Kennedy, S.S.M.D.P. Rosenfeld, S.A.P. Sands, K.M.D. Surapaneni, R.M.D. Lai, C.L.R.N. Yanes, E.P. Bagiella, and R.L.M.D. DeLaPaz Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan Neurosurgery 69 2011 1272 1280
29. S.L. Potter, S. Berg, A.M. Ingle, M. Krailo, P.C. Adamson, and S.M. Blaney Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962) Pediatr. Blood Cancer 58 2012 362 365
30. P.G. Rose, M.W. Sill, D.S. McMeekin, A. Ahmed, R. Salani, S.D. Yamada, A.H. Wolfson, N. Fusco, and P.M. Fracasso A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 125 2012 158 162
31. K.F. McGonigle, H.G. Muntz, J. Vuky, P.J. Paley, D.S. Veljovich, B.E. Greer, B.A. Goff, H.J. Gray, and T.W. Malpass Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study Cancer 117 2011 3731 3740
32. NCI cancer drug information: topotecan hydrochloride 2006
33. L.D. Mayer, L.C.L. Tai, M.B. Bally, G.N. Mitilenes, R.S. Ginsberg, and P.R. Cullis Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients Biochim. Biophys. Acta 1025 1990 143 151 (Pubitemid 20199621)
34. E. Ramsay, J. Alnajim, M. Anantha, A. Taggar, A. Thomas, K. Edwards, G. Karlsson, M. Webb, and M. Bally Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation Pharm. Res. 23 2006 2799 2808 (Pubitemid 44885367)
35. A.S. Taggar, J. Alnajim, M. Anantha, A. Thomas, M. Webb, E. Ramsay, and M.B. Bally Copper-topotecan complexation mediates drug accumulation into liposomes J. Control. Release 114 2006 78 88 (Pubitemid 44128628)
36. D.C. Drummond, C.O. Noble, Z. Guo, M.E. Hayes, C. Connolly-Ingram, B.S. Gabriel, B. Hann, B. Liu, J.W. Park, K. Hong, C.C. Benz, J.D. Marks, and D.B. Kirpotin Development of a highly stable and targetable nanoliposomal formulation of topotecan J. Control. Release 141 2010 13 21
37. G. Haran, R. Cohen, L.K. Bar, and Y. Barenholz Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim. Biophys. Acta 1151 1993 201 215 (Pubitemid 23283973)
38. E. Maurer-Spurej, K.F. Wong, N. Maurer, D.B. Fenske, and P.R. Cullis Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients Biochim. Biophys. Acta 1416 1999 1 10 (Pubitemid 29065419)
39. S.A. Abraham, K. Edwards, G. Karlsson, N. Hudon, L.D. Mayer, and M.B. Bally An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes J. Control. Release 96 2004 449 461 (Pubitemid 38553923)
40. J.-J. Liu, R.-L. Hong, W.-F. Cheng, K. Hong, F.-H. Chang, and Y.-L. Tseng Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation Anti-Cancer Drugs 13 2002 709 717
41. K.D. Fugit, and B.D. Anderson A dynamic, non-sink method for the simultaneous determination of drug permeability and binding coefficients in liposomes 2013 (In submission)
42. T.-X. Xiang, and B.D. Anderson Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified β-cyclodextrin Pharm. Res. 19 2002 1215 1222 (Pubitemid 34985007)
43. T.X. Xiang, and B.D. Anderson Permeability of acetic acid across gel and liquid-crystalline lipid bilayers conforms to free-surface-area theory Biophys. J. 72 1997 223 237 (Pubitemid 27043432)
44. T.-X. Xiang, and B.D. Anderson Influence of chain ordering on the selectivity of dipalmitoylphosphatidylcholine bilayer membranes for permeant size and shape Biophys. J. 75 1998 2658 2671 (Pubitemid 28548938)
45. J. Fassberg, and V.J. Stella A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues J. Pharm. Sci. 81 1992 676 684 (Pubitemid 23006796)
46. C.H. Huang A 13C and 2H nuclear magnetic resonance study of phosphatidylcholine/cholesterol interactions: characterization of liquid-gel phases Biochemistry 32 1993 11
47. V.R. Kodati, and M. Lafleur Comparison between orientational and conformational orders in fluid lipid bilayers Biophys. J. 64 1993 163 170 (Pubitemid 23063938)
48. M. Grit, and D.J.A. Crommelin Chemical stability of liposomes: implications for their physical stability Chem. Phys. Lipids 64 1993 3 18 (Pubitemid 23290861)
49. M. Grit, and D.J.A. Crommelin The effect of aging on the physical stability of liposome dispersions Chem. Phys. Lipids 62 1992 113 122
50. M. Grit, J.H. de Smidt, A. Struijke, and D.J.A. Crommelin Hydrolysis of phosphatidylcholine in aqueous liposome dispersions Int. J. Pharm. 50 1989 1 6 (Pubitemid 19049338)
51. N.J. Zuidam, and D.J.A. Crommelin Chemical hydrolysis of phospholipids J. Pharm. Sci. 84 1995 1113 1119
52. S.A. Strel'tsov, S.L. Grokhovskii, I.A. Kudelina, V.A. Oleinikov, and A.L. Zhuze Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 1. topotecan dimerization in solution Mol. Biol. 35 2001 365 373
53. A.S. Kearney, K. Patel, and N.R. Palepu Preformulation studies to aid in the development of a ready-to-use injectable solution of the antitumor agent, topotecan Int. J. Pharm. 127 1996 229 237 (Pubitemid 26091008)
54. M.R. di Nunzio, Y. Wang, and A. Douhal Structural spectroscopy and dynamics of inter- and intramolecular H-bonding interactions of topotecan, a potent anticancer drug, in organic solvents and in aqueous solution J. Phys. Chem. B 116 2012 7522 7530
55. V. Joguparthi, S. Feng, and B.D. Anderson Determination of intraliposomal pH and its effect on membrane partitioning and passive loading of a hydrophobic camptothecin, DB-67 Int. J. Pharm. 352 2008 17 28
56. J. Epstein, H.O. Michel, D.H. Rosenblatt, R.E. Plapinger, R.A. Stephani, and E. Cook Reactions of isopropyl methylphosphonofluoridate with substituted phenols. II J. Am. Chem. Soc. 86 1964 4959 4963
57. D. Bemporad, C. Luttmann, and J.W. Essex Behaviour of small solutes and large drugs in a lipid bilayer from computer simulations Biochim. Biophys. Acta 1718 2005 1 21 (Pubitemid 41698892)
58. T. Heimburg Lipid ion channels Biophys. Chem. 150 2010 2 22
59. R.W. Tejwani, T.R. Stouch, and B.D. Anderson Substituent effects on the ionization and partitioning of p-(aminoethyl)phenols and structurally related compounds: electrostatic effects dependent on conformation J. Pharm. Sci. 98 2009 4534 4544
60. O. Shirai, Y. Yoshida, and S. Kihara Voltammetric study on ion transport across a bilayer lipid membrane in the presence of a hydrophobic ion or an ionophore Anal. Bioanal. Chem. 386 2006 494 505 (Pubitemid 44450930)
61. O. Shirai, Y. Yoshida, S. Kihara, T. Ohnuki, A. Uehara, and H. Yamana Ion transport across a bilayer lipid membrane facilitated by gramicidin A - effect of counter anions on the cation transport J. Electroanal. Chem. 595 2006 53 59 (Pubitemid 44233606)